Ishita Drugs

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "70.50",
    "chg": -4.5,
    "chgp": "-6.0%",
    "dir": -1,
    "prev_price": "75.00",
    "mcapval": "22.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE806D01016",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "570 ",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Ishita Drugs & Industries Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ishita-drugs-industries-ltd-fallingrising-3792375",
        "imagepath": "",
        "date": "2026-01-15 00:43:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movement and Market Sentiment</strong></p>\n<p>The stock opened with a gap up of 4.26%, signalling renewed buying interest early in the session. It further climbed to an intraday high of ₹75.95, marking a 9.98% surge from the previous close. This sharp rebound came after four consecutive days of decline, suggesting a short-term trend reversal. Notably, Ishita Drugs outperformed its sector by 5.98% on the day, indicating relative strength amid broader market pressures.</p>\n<p>Investor participation has also increased significantly, with delivery volumes on 13 Jan rising by 162.97% compared to the five-day average. This surge in volume points to heightened investor interest, potentially driven by the stock’s attractive valuation metrics and recent profit growth, despite its recen..."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Mixed Fundamentals and Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amid-mixed-fundamentals-and-technicals-3782570",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IshitaDrugsIndu_mojoScore_3782570.png",
        "date": "2026-01-06 08:21:38",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting a deterioration in technical indicators and persistent fundamental weaknesses. Despite a modest uptick in share price and some valuation appeal, the company’s financial trends and technical signals have raised concerns among analysts, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-upgraded-to-sell-on-technical-improvements-despite-flat-financials-3774372",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IshitaDrugsIndu_mojoScore_3774372.png",
        "date": "2025-12-30 08:21:10",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Dec 2025, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s Mojo Score rose to 34.0, reflecting a modest improvement in market sentiment, while its valuation and financial trends continue to pose challenges for investors."
      },
      {
        "title": "Ishita Drugs & Industries Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-is-rated-strong-sell-3770886",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IshitaDrugsIndu_mojoScore_3770886.png",
        "date": "2025-12-26 15:13:38",
        "description": "Ishita Drugs & Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 October 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Ishita Drugs Sees Revision in Market Assessment Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3750585",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IshitaDrugs_mojoScore_3750585.png",
        "date": "2025-12-08 10:10:34",
        "description": "Ishita Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment highlights ongoing challenges in the company’s financial and operational metrics, which investors should consider carefully."
      },
      {
        "title": "How has been the historical performance of Ishita Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-ishita-drugs-3694511",
        "imagepath": "",
        "date": "2025-11-12 23:42:54",
        "description": "Answer:\nThe historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years.\n\nBreakdown:\nIshita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 20..."
      },
      {
        "title": "Are Ishita Drugs latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-latest-results-good-or-bad-3693150",
        "imagepath": "",
        "date": "2025-11-12 19:26:54",
        "description": "Ishita Drugs' latest financial results for Q2 FY26 indicate significant operational challenges. The company reported net sales of ₹3.07 crores, reflecting a sharp quarter-on-quarter decline of 43.15% from ₹5.40 crores in Q1 FY26. This substantial drop in revenue has translated into a corresponding decrease in profitability, with net profit falling to ₹0.14 crores, a decline of 53.33% from the previous quarter.\n\nThe operating margin also contracted, decreasing to 6.19%, down from 6.48% in Q1 FY26, while the PAT margin fell to 4.56%, a reduction of 100 basis points. These metrics suggest that the company is facing difficulties in maintaining consistent order flows and pricing power amid a competitive landscape in the pharmaceutical ingredients sector.\n\nDespite a year-on-year comparison showing only a 6.12% decline in net sales from ₹3.27 crores in Q2 FY25, the sequential performance highlights a concerning vo..."
      },
      {
        "title": "Ishita Drugs Faces Mixed Financial Trends Amidst Sales Growth and Liquidity Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-financial-trend-declines-from-flat-to-negative-amid-weak-performance-indicators-3692418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IshitaDrugsIndu_fintrenddot_3692418.png",
        "date": "2025-11-12 11:00:51",
        "description": "Ishita Drugs & Industries has reported a flat performance for the quarter ending September 2025, despite a notable 34.44% growth in net sales to Rs 8.47 crore. However, the company faces challenges with low operating cash flow and declining profit metrics, reflecting mixed performance in a competitive market."
      },
      {
        "title": "Ishita Drugs Q2 FY26: Sharp Sequential Decline Raises Concerns Despite YoY Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q2-fy26-sharp-sequential-decline-raises-concerns-despite-yoy-growth-3692504",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IshitaDrugsIndu_quaterlyResult_3692504.png",
        "date": "2025-11-12 09:38:13",
        "description": "Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharma ingredients and drug intermediates, reported a concerning quarter-on-quarter decline in its Q2 FY26 results, with net profit falling 53.33% sequentially to ₹0.14 crores despite posting a modest year-on-year decline of 26.32%. The company's shares, trading at ₹72.49 with a market capitalisation of ₹22.00 crores, have declined 21.57% year-to-date, reflecting investor concerns about the company's operational momentum and competitive positioning in the pharmaceutical ingredients space."
      }
    ],
    "total": 105,
    "sid": "444125",
    "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31st December 2025 as attached.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Of Change In Address Of Registrar And Share Transfer Agent (RTA) (Ahmedabad Branch)",
      "datetime": "02-Jan-2026",
      "details": "Change in Address of our RTA i.e. Bigshare Services Private Limited (Ahmedabad Branch)",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "31-Dec-2025",
      "details": "Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Mr. Jagdish Agrawal Promoter (M.D.)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Ishita Drugs & Industries Ltd falling/rising?

2026-01-15 00:43:51

Intraday Price Movement and Market Sentiment

The stock opened with a gap up of 4.26%, signalling renewed buying interest early in the session. It further climbed to an intraday high of ₹75.95, marking a 9.98% surge from the previous close. This sharp rebound came after four consecutive days of decline, suggesting a short-term trend reversal. Notably, Ishita Drugs outperformed its sector by 5.98% on the day, indicating relative strength amid broader market pressures.

Investor participation has also increased significantly, with delivery volumes on 13 Jan rising by 162.97% compared to the five-day average. This surge in volume points to heightened investor interest, potentially driven by the stock’s attractive valuation metrics and recent profit growth, despite its recen...

Read full news article

Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Mixed Fundamentals and Technicals

2026-01-06 08:21:38

Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting a deterioration in technical indicators and persistent fundamental weaknesses. Despite a modest uptick in share price and some valuation appeal, the company’s financial trends and technical signals have raised concerns among analysts, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

2025-12-30 08:21:10

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Dec 2025, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s Mojo Score rose to 34.0, reflecting a modest improvement in market sentiment, while its valuation and financial trends continue to pose challenges for investors.

Read full news article

Ishita Drugs & Industries Ltd is Rated Strong Sell

2025-12-26 15:13:38

Ishita Drugs & Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 October 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and outlook.

Read full news article

Ishita Drugs Sees Revision in Market Assessment Amidst Challenging Fundamentals

2025-12-08 10:10:34

Ishita Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment highlights ongoing challenges in the company’s financial and operational metrics, which investors should consider carefully.

Read full news article

How has been the historical performance of Ishita Drugs?

2025-11-12 23:42:54

Answer: The historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years. Breakdown: Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 20...

Read full news article

Are Ishita Drugs latest results good or bad?

2025-11-12 19:26:54

Ishita Drugs' latest financial results for Q2 FY26 indicate significant operational challenges. The company reported net sales of ₹3.07 crores, reflecting a sharp quarter-on-quarter decline of 43.15% from ₹5.40 crores in Q1 FY26. This substantial drop in revenue has translated into a corresponding decrease in profitability, with net profit falling to ₹0.14 crores, a decline of 53.33% from the previous quarter. The operating margin also contracted, decreasing to 6.19%, down from 6.48% in Q1 FY26, while the PAT margin fell to 4.56%, a reduction of 100 basis points. These metrics suggest that the company is facing difficulties in maintaining consistent order flows and pricing power amid a competitive landscape in the pharmaceutical ingredients sector. Despite a year-on-year comparison showing only a 6.12% decline in net sales from ₹3.27 crores in Q2 FY25, the sequential performance highlights a concerning vo...

Read full news article

Ishita Drugs Faces Mixed Financial Trends Amidst Sales Growth and Liquidity Challenges

2025-11-12 11:00:51

Ishita Drugs & Industries has reported a flat performance for the quarter ending September 2025, despite a notable 34.44% growth in net sales to Rs 8.47 crore. However, the company faces challenges with low operating cash flow and declining profit metrics, reflecting mixed performance in a competitive market.

Read full news article

Ishita Drugs Q2 FY26: Sharp Sequential Decline Raises Concerns Despite YoY Growth

2025-11-12 09:38:13

Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharma ingredients and drug intermediates, reported a concerning quarter-on-quarter decline in its Q2 FY26 results, with net profit falling 53.33% sequentially to ₹0.14 crores despite posting a modest year-on-year decline of 26.32%. The company's shares, trading at ₹72.49 with a market capitalisation of ₹22.00 crores, have declined 21.57% year-to-date, reflecting investor concerns about the company's operational momentum and competitive positioning in the pharmaceutical ingredients space.

Read full news article

View All News